Benjamin Landman is a child psychiatrist. He is chief resident at the Excellence Center for Autism and Neurodevelopmental Disorders at the Robert Debré Hospital, in Paris, France. He has a major interest in the identification of biomarkers in autism. He is mainly involved in the project SoNeTAA (Social Neuroscience for Therapeutic Approaches in Autism) and combines human-human and human-machine interactions with electroencephalography recording to study social cognition from a situated and reciprocal standpoint. The project aims to bridge the gap between state-of-the-art social neuroscience methods and clinical practices. He is also co-founder of the www.debrechildpsychiatry.org website.
Benjamin Landman
Chief resident
Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders
From this contributor
Coronavirus tool kit may aid families with autistic children during lockdown
To help families cope with the sudden loss of professional support during the pandemic, one team in France has created a set of resources and information.
Coronavirus tool kit may aid families with autistic children during lockdown
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.